Ticagrelor Production Process for Amorphous Formulation Stability

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Ticagrelor formulations face challenges with low bioavailability due to its low solubility and permeability, requiring particle size adjustment which can lead to degradation, polymorphic changes, and poor flow properties, increasing production complexity and cost.

Innovation Solution

A particle size independent production method where ticagrelor is dissolved or dispersed in a solvent mixture, followed by wet granulation with excipients, allowing for consistent solubility and content uniformity without pre-adjusting particle size, using solvents like methanol, ethanol, or dimethyl sulfoxide, and incorporating fillers, binders, and lubricants to enhance formulation stability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If particle size is minimized to improve solubility and content uniformity, then solubility and content uniformity are improved, but physical stability deteriorates due to polymorphic changes and amorphous formation

Engineering Contradiction:
Improvecontent uniformityVSAvoidpolymorphic stability
Core Design Contradiction:
Manufacturing precisionVSStability of the object's composition

Solution Approach 1:

The patent changes the physical-chemical parameters of ticagrelor by converting it from crystalline form to amorphous form through spray drying process. This parameter change enables the material to achieve high solubility and content uniformity without requiring further particle size minimization that would compromise stability. The amorphous state represents a different physical parameter state that inherently provides both improved dissolution and stability.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent utilizes phase transition from crystalline to amorphous state through spray drying. The spray drying process rapidly evaporates solvent from a liquid solution, inducing phase transition to amorphous solid. This phase transition achieves the dual benefit of improved solubility (amorphous forms dissolve faster) and stability (controlled amorphous formation without continued particle degradation).

Inventive Principle:
Principle #36Phase transitions

2Manufacturing precision

If particle size is minimized to improve solubility, then solubility is improved, but flow properties deteriorate leading to production difficulties

Engineering Contradiction:
ImprovesolubilityVSAvoidflow properties
Core Design Contradiction:
Manufacturing precisionVSEase of manufacture

Solution Approach 1:

The patent changes the physical state parameter from crystalline to amorphous, which fundamentally alters the material properties. The amorphous form achieves high solubility without requiring extreme particle size minimization. Additionally, the spray drying process produces particles with controlled morphology that maintain acceptable flow properties, resolving the contradiction between solubility improvement and manufacturing ease.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

Instead of continuing to minimize particle size in one dimension (which harms flow properties), the patent transitions to a different dimensional approach by changing the physical state from crystalline to amorphous. This dimensional change in the phase space allows achieving solubility improvement through molecular arrangement rather than particle size reduction, thereby preserving flow properties.

Inventive Principle:
Principle #17Another dimension (Dimensionality change)

3Manufacturing precision

If grinding techniques are used to adjust particle size, then solubility and content uniformity are improved, but production complexity and cost increase

Engineering Contradiction:
Improvecontent uniformityVSAvoidproduction process complexity
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent merges multiple functions into a single spray drying process: dissolution of ticagrelor, formation of amorphous state, particle size control, and content uniformity achievement all occur in one operation. This eliminates the need for separate grinding, classification, and formulation steps, thereby reducing production complexity and equipment requirements while achieving the desired manufacturing precision.

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The spray drying process uses parameter changes (temperature, humidity, spray rate, air flow) to directly achieve the desired particle characteristics and amorphous formation in one step. This parameter-based approach replaces mechanical particle size reduction with a chemical-physical transformation, simplifying the production process and reducing the number of unit operations required.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method achieves consistent solubility and content uniformity across various particle sizes, improving dissolution profiles and stability compared to existing products like Brilanta, with reduced production complexity and cost.

Implementation Method 1

ticagrelor active ingredient is dissolved and/or dispersed in a solvent

Methodology Applied
Scientific EffectDissolution: Solvation

Implementation Method 2

ticagrelor active ingredient is dissolved and/or dispersed in a solvent

Methodology Applied
Scientific EffectDispersion: Dispersion (of waves)

Implementation Method 3

wet granulation with excipients

Methodology Applied
Scientific EffectGranulation:

Data Source

PatentEP3266447B1Production process for formulations containing ticagrelor
Publication Date: 2021.03.03 ALI RAIF ILAC SAN AS
  • EP3266447B1 patent drawing
  • EP3266447B1 patent drawing

AI summary

This present invention is related to production process of formulations containing ticagrelor and use of these formulations in the prevention of thrombotic events in patients with acute coronery syndrome.